- Home
- SNES vs HIND Comparison
SNES vs HIND Comparison
Compare SNES & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNES | HIND |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 12.9M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SNES | HIND |
|---|---|---|
| Price | $1.76 | $2.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.9K | ★ 57.8K |
| Earning Date | 03-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,000.00 | N/A |
| Revenue This Year | $29.00 | N/A |
| Revenue Next Year | $95.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.56 | N/A |
| 52 Week Low | $1.30 | $1.75 |
| 52 Week High | $5.99 | $12.87 |
Technical Indicators
Market Signals| Indicator | SNES | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 40.69 |
| Support Level | $1.67 | $2.02 |
| Resistance Level | $2.26 | $2.93 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 5.00 | 28.87 |
Price Performance
Historical ComparisonAbout SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.